Literature DB >> 27684100

Pre-clinical Orthotopic Murine Model of Human Prostate Cancer.

Varahram Shahryari1, Hannah Nip1, Sharanjot Saini1, Altaf A Dar2, Soichiro Yamamura1, Yozo Mitsui1, Melissa Colden1, Nathan Bucay1, Laura Z Tabatabai1, Kirsten Greene1, Guoren Deng1, Yuichiro Tanaka1, Rajvir Dahiya1, Shahana Majid3.   

Abstract

To study the multifaceted biology of prostate cancer, pre-clinical in vivo models offer a range of options to uncover critical biological information about this disease. The human orthotopic prostate cancer xenograft mouse model provides a useful alternative approach for understanding the specific interactions between genetically and molecularly altered tumor cells, their organ microenvironment, and for evaluation of efficacy of therapeutic regimens. This is a well characterized model designed to study the molecular events of primary tumor development and it recapitulates the early events in the metastatic cascade prior to embolism and entry of tumor cells into the circulation. Thus it allows elucidation of molecular mechanisms underlying the initial phase of metastatic disease. In addition, this model can annotate drug targets of clinical relevance and is a valuable tool to study prostate cancer progression. In this manuscript we describe a detailed procedure to establish a human orthotopic prostate cancer xenograft mouse model.

Entities:  

Year:  2016        PMID: 27684100      PMCID: PMC5091966          DOI: 10.3791/54125

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  20 in total

1.  Orthotopic implantation of human prostate cancer cell lines: a clinically relevant animal model for metastatic prostate cancer.

Authors:  K Rembrink; J C Romijn; T H van der Kwast; H Rübben; F H Schröder
Journal:  Prostate       Date:  1997-05-15       Impact factor: 4.104

2.  Pre-clinical mouse models of human prostate cancer and their utility in drug discovery.

Authors:  Serk In Park; Sun Jin Kim; Laurie K McCauley; Gary E Gallick
Journal:  Curr Protoc Pharmacol       Date:  2010-12

3.  High-malignancy orthotopic nude mouse model of human prostate cancer LNCaP.

Authors:  X Wang; Z An; J Geller; R M Hoffman
Journal:  Prostate       Date:  1999-05-15       Impact factor: 4.104

4.  GFP-transfected tumor cells are useful in examining early metastasis in vivo, but immune reaction precludes long-term tumor development studies in immunocompetent mice.

Authors:  Markus Steinbauer; Markus Guba; Grigore Cernaianu; Gudrun Köhl; Michaela Cetto; Leoni A Kunz-Schughart; Edward K Geissler; Werner Falk; Karl-Walter Jauch
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

5.  A fluorescent orthotopic bone metastasis model of human prostate cancer.

Authors:  M Yang; P Jiang; F X Sun; S Hasegawa; E Baranov; T Chishima; H Shimada; A R Moossa; R M Hoffman
Journal:  Cancer Res       Date:  1999-02-15       Impact factor: 12.701

6.  AFAP-110 is overexpressed in prostate cancer and contributes to tumorigenic growth by regulating focal contacts.

Authors:  Jing Zhang; Serk In Park; Marlene C Artime; Justin M Summy; Ami N Shah; Joshua A Bomser; Andrea Dorfleutner; Daniel C Flynn; Gary E Gallick
Journal:  J Clin Invest       Date:  2007-10       Impact factor: 14.808

7.  Blockade of epidermal growth factor receptor signaling in tumor cells and tumor-associated endothelial cells for therapy of androgen-independent human prostate cancer growing in the bone of nude mice.

Authors:  Sun-Jin Kim; Hisanori Uehara; Takashi Karashima; David L Shepherd; Jerald J Killion; Isaiah J Fidler
Journal:  Clin Cancer Res       Date:  2003-03       Impact factor: 12.531

8.  Reduced c-Met expression by an adenovirus expressing a c-Met ribozyme inhibits tumorigenic growth and lymph node metastases of PC3-LN4 prostate tumor cells in an orthotopic nude mouse model.

Authors:  Sun Jin Kim; Marjorie Johnson; Kristen Koterba; Matthew H Herynk; Hisanori Uehara; Gary E Gallick
Journal:  Clin Cancer Res       Date:  2003-11-01       Impact factor: 12.531

9.  Heat shock protein 27 confers resistance to androgen ablation and chemotherapy in prostate cancer cells through eIF4E.

Authors:  C Andrieu; D Taieb; V Baylot; S Ettinger; P Soubeyran; A De-Thonel; C Nelson; C Garrido; A So; L Fazli; F Bladou; M Gleave; J L Iovanna; P Rocchi
Journal:  Oncogene       Date:  2010-01-18       Impact factor: 9.867

10.  An orthotopic murine model of human prostate cancer metastasis.

Authors:  Janet Pavese; Irene M Ogden; Raymond C Bergan
Journal:  J Vis Exp       Date:  2013-09-18       Impact factor: 1.355

View more
  3 in total

1.  Optimization and Characterization of a Bone Culture Model to Study Prostate Cancer Bone Metastasis.

Authors:  Yi-Hsuan Wu; Zbigniew Gugala; Megan M Barry; Yichao Shen; Subhamoy Dasgupta; Hai Wang
Journal:  Mol Cancer Ther       Date:  2022-08-02       Impact factor: 6.009

2.  Humanization of the Prostate Microenvironment Reduces Homing of PC3 Prostate Cancer Cells to Human Tissue-Engineered Bone.

Authors:  Jacqui A McGovern; Abbas Shafiee; Ferdinand Wagner; Christoph A Lahr; Marietta Landgraf; Christoph Meinert; Elizabeth D Williams; Pamela J Russell; Judith A Clements; Daniela Loessner; Boris M Holzapfel; Gail P Risbridger; Dietmar W Hutmacher
Journal:  Cancers (Basel)       Date:  2018-11-13       Impact factor: 6.639

3.  Heterozygous deletion of chromosome 17p renders prostate cancer vulnerable to inhibition of RNA polymerase II.

Authors:  Yujing Li; Yunhua Liu; Hanchen Xu; Guanglong Jiang; Kevin Van der Jeught; Yuanzhang Fang; Zhuolong Zhou; Lu Zhang; Michael Frieden; Lifei Wang; Zhenhua Luo; Milan Radovich; Bryan P Schneider; Yibin Deng; Yunlong Liu; Kun Huang; Bin He; Jin Wang; Xiaoming He; Xinna Zhang; Guang Ji; Xiongbin Lu
Journal:  Nat Commun       Date:  2018-10-22       Impact factor: 14.919

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.